This Article Résumé de cet Article Full Text Full Text (PDF) Submit a scholarly reply Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sarkar, P. Articles by Hall, G. Search for Related Content PubMed PubMed Citation Articles by Sarkar, P. Articles by Hall, G.

Brief review: Angiotensin converting enzyme inhibitors and angioedema: anesthetic implications

[Revue sommaire sur les implications anesthésiques de l’dème de Quincke et des inhibiteurs de l’enzyme de conversion de l’angiotensine]

From the Department of Anaesthesia and Intensive Care Medicine, St George’s Hospital Medical School, London, UK.

Address correspondence to: Dr. Grainne Nicholson, Dept. of Anaesthesia, St George’s Hospital Medical School, London SW17 0RE, UK. Phone: 0044 208 725 3629; Fax: 0044 208 725 0256; E-mail: gnichols{at}sgul.ac.uk

Purpose: Angiotensin converting enzyme inhibitors (ACEIs) are a group of drugs used to treat hypertension and heart failure, with additional benefits, such as cardiovascular and renal protection, in patients with diabetes. However, angioedema as a complication of ACEI therapy is under-recognized. As there are important implications for anesthesiologists and emergency medicine physicians, a review was undertaken to document the scope of the problem of ACEI-induced angioedema..

Methods: A review of the published literature (identified by searching Medline, EMBASE and CINAHL) was undertaken, addressing the clinical uses of ACEIs and the incidence, risk factors, pathophysiology, clinical presentation and management of angioedema associated with the use of these drugs.

Principal findings: The incidence of ACEI related angioedema has increased from 0.1–0.2% to 1% over the last decade. Patients who are receiving ACEIs are predisposed to developing angioedema which may be triggered by trauma, airway instrumentation, infection, and irritant fumes, particularly in those who are at increased risk. Cases of acute facial and airway oedema, due to ACEI drug administration, may be misdiagnosed as an anaphylactic reaction, and the association with ACEIs may be ignored. Some cases of intraoperative and postoperative airway edema may be precipitated by airway instrumentation in patients receiving ACEI drugs. The severity of airway compromise ranges from mild facial edema to severe laryngeal or subglottic edema which may prove life-threatening.

Conclusion: In view of the widespread clinical indications and ever-increasing use of ACEI drugs, the potentially life-threatening adverse reaction of ACEI-associated angioedema, and its treatment, must be recognized by anesthesiologists and all clinicians involved in airway management.

This article has been cited by other articles:

				A. Kapoor, P. Jefferson, and D. R. Ball Airway management in angiotensin converting enzyme inhibitor related angioedema Can J Anesth, March 1, 2007; 54(3): 242 - 242. [Full Text] [PDF]

				Y. U. Adachi, S. Iwakiri, and T. Katoh Angioedema, angiotensin converting enzyme inhibitors, and angiotensin receptor blocking drugs Can J Anesth, February 1, 2007; 54(2): 155 - 157. [Full Text]